Could serum endocannabinoid and N-acylethanolamine levels be important in bipolar disorder?

Basit Öğe Kaydı
dc.authoridGorgulu, Yasemin/0000-0002-3401-4879
dc.authorwosidGorgulu, Yasemin/S-4355-2017
dc.contributor.authorTopuz, Ruhan Deniz
dc.contributor.authorGorgulu, Yasemin
dc.contributor.authorUluturk, Milkibar Kyazim
dc.date.accessioned2024-06-12T10:54:42Z
dc.date.available2024-06-12T10:54:42Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives The endocannabinoid system (ECS) is a critical important neuromodulatory system that interacts with many neurohormonal and neurotransmitter systems in the brain. It plays a pivotal role in emotional responses and mood regulation. The ECS is related with psychotic disorders, depression, anxiety and autism. In this study, we aimed to investigate whether there is any relationship between endocannabinoid and N-acylethanolamine levels with bipolar disorder. Methods Seventy-nine patients with bipolar disorder diagnosis, who are in the euthymic period, were included in the study. Clinical characteristics, symptoms and serum endocannabinoid and N-acylethanolamine levels were compared. Endocannabinoid and N-acylethanolamine levels were evaluated using liquid chromatography-tandem mass spectrometry. Results In total of 79 patients, 44 (55.69%) were females and 35 (44.30%) were males. The mean age of the patients was 42.40 +/- 1.10 years. Palmitoylethanolamide (PEA) levels were higher and oleoylethanolamide and 2-arachidonyl glycerol levels were lower in patients who had at least one depressive episode during their life-time illness than in patients who had no depressive episode while arachidonyl ethanolamide levels were unchanged Conclusions PEA levels were correlated with the history and frequency of depressive episodes and the history of depressive symptoms in patients with bipolar disorder.en_US
dc.description.sponsorshipTrakya University Research Council [TUBAP 2021/57]en_US
dc.description.sponsorshipThis work was supported by a grant from Trakya University Research Council (TUBAP 2021/57).en_US
dc.identifier.doi10.1080/15622975.2022.2111713
dc.identifier.endpage320en_US
dc.identifier.issn1562-2975
dc.identifier.issn1814-1412
dc.identifier.issue4en_US
dc.identifier.pmid35950574en_US
dc.identifier.scopus2-s2.0-85136467678en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage314en_US
dc.identifier.urihttps://doi.org/10.1080/15622975.2022.2111713
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19155
dc.identifier.volume24en_US
dc.identifier.wosWOS:000843070800001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofWorld Journal Of Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBipolar Disorderen_US
dc.subjectEndocannabinoiden_US
dc.subjectN-Acylethanolamineen_US
dc.subjectDepressionen_US
dc.subjectManic Episodeen_US
dc.subjectCannabis Useen_US
dc.subjectSystemen_US
dc.subjectOnseten_US
dc.subjectAgeen_US
dc.titleCould serum endocannabinoid and N-acylethanolamine levels be important in bipolar disorder?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu